Please assess the completion status of the following clinical trial:

Trial Title: A Study of Prucalopride For Functional Constipation in Children and Teenagers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Participants and/or their parent(s)/caregiver(s)/legally authorized representative(s) have an understanding, ability, and willingness to fully comply with study procedures and restrictions.~* Ability to voluntarily provide written, signed, and dated (personally or via parent\[s\]/caregiver\[s\]/legally authorized representative\[s\]) informed consent/assent as applicable to participate in the study.~Note: Participants and/or parent(s)/caregiver(s)/legally authorized representative(s) (where appropriate depending on age and local regulation) can also provide consent/assent to the sparse Pharmacokinetic (PK) sampling in this study.~* Toilet-trained participants 3 years to 17 years of age, inclusive, or non-toilet-trained participants 6 months to 17 years of age, inclusive.~* Participant weighs greater than or equal to (\>=) 5.5 kilograms (kg) (12 pounds \[lbs\]).~* Male, or non-pregnant, non-lactating female participants who are sexually active and agree to comply with the applicable contraceptive requirements of the protocol or females of non-childbearing potential.~Note: All female participants \>= 12 years and/or female participants lesser than (\<) 12 years who have started menarche must have a negative serum pregnancy test at screening.~- Participant meets modified Rome IV criteria:~\* For child/adolescent (aged \> 4 years) functional constipation (H3a):~Participants must have lesser than or equal to (\<=) 2 defecations per week and 1 or more of the following occurring at least once per week for a minimum of 1 month:~* \>= 1 episode of fecal incontinence per week (only for participants after the acquisition of toileting skills).~* History of retentive posturing or excessive volitional stool retention.~* History of painful or hard bowel movements (BMs).~* Presence of large fecal mass in rectum.~* History of large diameter stools which can obstruct the toilet. In addition, the participant does not satisfy sufficient criteria for a diagnosis of irritable bowel syndrome (IBS) and, after appropriate evaluation, the participants symptoms cannot be fully explained by another medical condition.~For infants/toddler (aged 6 months to \<= 4 years) functional constipation (G7):~Participants must have \<= 2 defecations per week and \>= 1 month of at least 1 of the following:~* History of excessive stool retention~* History of painful or hard BMs~* History of large-diameter stools (in the diaper)~* Presence of a large fecal mass in the rectum~In toilet-trained children, the following additional criteria may be used:~* At least 1 episode/week of incontinence after the acquisition of toileting skills~* History of large-diameter stools which may obstruct the toilet - Participant and/or parent(s)/caregiver(s)/legally authorized representative(s) is willing to discontinue any laxatives during the screening period up to disimpaction and agrees to adhere to the protocol-specified disimpaction and rescue medication rules, if applicable.~To be evaluated prior to randomization:~* Participant has an average of \< 3 SBMs (defecations) per week during the screening period and prior to the disimpaction.~* Participant or legally authorized representative (dependent on participant age) is compliant with completing the electronic diary for at least 7 consecutive days preceding the disimpaction.~Exclusion Criteria:~* Current or recurrent disease that could affect the action, absorption, or disposition of the investigational product (IP), or clinical or laboratory assessments.~* Any clinically significant abnormal findings on the electrocardiogram (ECG) that indicates a dysrhythmia or conduction abnormalities (such as abnormal heart rate, PR, QRS, or QT).~* Major cardiovascular disease such as: cardiomyopathy, cardiac insufficiency, uncorrected congenital heart disease, symptomatic valve disorders, or septal defects.~* Current or relevant history of physical or psychiatric illness (e.g. severe autism, depression, etc.), any medical disorder that may require treatment or make the participant unlikely to fully complete the study, or any condition that presents undue risk from the IP or procedures.~* Non-retentive fecal incontinence.~* Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract such as Crohn's disease, ulcerative colitis, and toxic megacolon/megarectum.~* Current use of any medication (including over-the-counter, herbal, or homeopathic preparations) that could affect (improve or worsen) the condition being studied (e.g. opioids), or could affect the action, absorption, or disposition of the IP, or clinical or laboratory assessment. (Current use is defined as use within the past 5 days).~* Participants with renal impairment:~  * Participants \<= 2 years of age with serum creatinine greater than normal (screening sample results using central laboratory pediatric reference ranges).~ * Participants \> 2 years of age with severe renal impairment or end stage renal disease (estimated glomerular filtration rate \[eGFR\] \<30 mL/min/1.73 m\^2).~* Known or suspected intolerance or hypersensitivity to the IP(s), closely-related compounds, or any of the stated ingredients.~* Known history of alcohol or other substance abuse within the last year.~* Within 30 days prior to the first dose of the IP in the current study:~  * Have used any IP.~ * Have been enrolled in a clinical study (including vaccine studies) that may or may not include the administration of an IP that, in the investigator's opinion, may impact this study.~* Participant used prucalopride within 10 days prior to the first dose of the IP or has been unsuccessfully treated with prucalopride before.~* Participant meets Rome IV criteria for other Child/Adolescent Functional Gastrointestinal Disorders (FGID) (H1 - H2 and H3b).~* Participant with secondary causes of constipation:~  * Endocrine disorders (e.g., hypopituitarism, hypothyroidism, hypercalcemia, pheochromocytoma, glucagon-producing tumors) unless these are controlled by appropriate medical therapy. Participant with uncontrolled diabetes mellitus is to be excluded~ * Metabolic disorders (e.g. porphyria, uremia, hypokalemia, hypothyroidism, amyloid neuropathy), unless controlled by appropriate medical therapy~ * Neurological disorders (e.g. cerebral tumors, cerebrovascular accidents, multiple sclerosis, meningocele, aganglionosis, hypoganglionosis, hyperganglionosis, autonomic neuropathy, spinal cord injury, Chagas disease~ * Organic disorders (known or suspected) of the large bowel (e.g. obstruction from any cause including biliary obstruction, malignancy, intestinal perforation, obstructive ileus, pseudo-obstruction, history of or current anorectal malformations, severe inflammation of the intestinal tract, such as Crohn's disease, ulcerative colitis or toxic megacolon/megarectum, Hirschsprung's disease)~ * Celiac disease, cow milk allergy~ * Surgery: history of gastrointestinal surgery related or possibly related to the presence of constipation~ * Lactose intolerance~* Any of the following clinically significant abnormalities of serum biochemistry:~  * Serum aspartate aminotransferase (AST) \>1.5 times upper limit of normal (ULN) at screening.~ * Serum alanine aminotransferase (ALT) \>1.5 times ULN at screening.~ * Total bilirubin outside the age-adjusted normal range, except for participants with Gilbert's syndrome.~* Any significant underlying liver disease.~* Participant is not able to swallow the IP (liquid or tablet).~* Participant is pregnant or planning to get pregnant during study period.~To be evaluated prior to randomization:~* Participant has used other disimpaction medication in lieu of the protocol-provided medication.~* Participant has used non-protocol approved medications to induce BMs during the screening period or disimpaction.~* The participant has failed the disimpaction based on the investigator's assessment.~* Worsening of depression and emergence of suicidal thoughts.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Part A: Placebo (Type: PLACEBO_COMPARATOR): Participants weighing \<50 kilograms (kg) will draw equal volumes from two bottles of placebo oral solution to account for the daily dose assigned or participants weighing ≥ 50 kg will receive two placebo oral tablets, once daily (QD), during 12 weeks in Part A. Prucalopride matching placebo (oral solution or tablet) will be dosed depending on the participant's body weight (BW) at the randomization visit.
- Part A: Low Dose Prucalopride (Type: EXPERIMENTAL): Participants weighing \<50 kg will receive 0.04 milligrams per kilogram (mg/kg) of prucalopride oral solution (will draw the required volume from one bottle of 0.4 milligram per milliliter \[mg/mL\] and one bottle of placebo oral solution), QD or participants weighing ≥50 kg will receive one 2 milligram (mg) of prucalopride oral tablet and one placebo oral tablet, QD, during 12 weeks in Part A. Prucalopride (oral solution or tablet) will be dosed depending on the participant's BW at the randomization visit.
- Part A: High Dose Prucalopride (Type: EXPERIMENTAL): Participants weighing \<50 kg will receive 0.08 mg/kg of prucalopride oral solution (will draw the required volume from two bottles of 0.4 mg/mL to account for the daily dose assigned), QD or participants weighing ≥50 kg will receive two 2 mg of prucalopride oral tablets, QD, during 12 weeks of treatment period in Part A. Prucalopride (oral solution or tablet) will be dosed depending on the participant's BW at the randomization visit.
- Part B: Low Dose Prucalopride (Type: EXPERIMENTAL): Participants weighing \<50 kg will receive 0.04 mg/kg of prucalopride oral solution (will draw the required volume from one bottle of 0.4 mg/mL and one bottle of placebo oral solution to account for the daily dose assigned), QD or participants weighing ≥50 kg will receive one 2 mg of prucalopride oral tablet and one placebo oral tablet, QD, for 36 weeks during the 40-week Part B Period. Prucalopride (oral solution or tablet) will be dosed depending on the participant's BW at the randomization visit.
- Part B: High Dose Prucalopride (Type: EXPERIMENTAL): Participants weighing \<50 kg will receive 0.08 mg/kg of prucalopride oral solution (will draw the required volume from two bottles of 0.4 mg/mL to account for the daily dose assigned), QD or participants weighing ≥50 kg will receive two 2 mg of prucalopride oral tablets, QD, for 36 weeks during the 40-week Part B Period. Prucalopride (oral solution or tablet) will be dosed depending on the participant's BW at the randomization visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).